Prospective evaluation of morphological and functional changes after repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion

Ophthalmic Research

Volumn 53, Issue 4, 2015, Pages 207-216

  Bandello, Francesco ^a   Parravano, Mariacristina ^b   Cavallero, Edoardo ^a   Cascavilla, Maria Lucia ^a   Triolo, Giacinto ^a   Querques, Lea ^a   Borrelli, Enrico ^a   Giorno, Paola ^b   Varano, Monica ^b   Lattanzio, Rosangela ^a   Querques, Giuseppe ^a,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Dexamethasone implant; Microperimetry; Optical coherence tomography; Ozurdex ; Retinal vein occlusion

Indexed keywords

DEXAMETHASONE; ANTIINFLAMMATORY AGENT; DELAYED RELEASE FORMULATION; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL MACULAR THICKNESS; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; INTRAVITREAL IMPLANT; MACULAR EDEMA; MALE; OUTCOME ASSESSMENT; PERIMETRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINAL THICKNESS; RETREATMENT; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; AGED; DELAYED RELEASE FORMULATION; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RETINA MACULA LUTEA; RETINAL VEIN OCCLUSION; THERAPEUTIC USE;

AGED; ANTI-INFLAMMATORY AGENTS; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DRUG IMPLANTS; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; VISUAL ACUITY;

EID: 84928159165     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000381187     Document Type: Article

References (20)

1. Ehlers JP, Fekrat S: Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 2011; 56: 281-299.
2. The Branch Vein Occlusion Study Group: Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984; 98: 271-282.
3. The Central Vein Occlusion Study Group M report: Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology 1995; 102: 1425-1433.
4. Bressler NM, Schachat AP: Management of macular edema from retinal vein occlusions: you can never have too many choices. Ophthalmology 2010; 117: 1061-1063.
5. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1146.
6. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453-2460.
7. Goldfien A: Adrenocorticosteroids and adrenocortical antagonists; in Katzung BG (ed): Basic and Clinical Pharmacology, ed 6. London, Prentice Hall International 1995, pp 592-607.
8. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group: Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema . Arch Ophthalmol 2007; 125: 309-317.
9. Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, Cascavilla ML, Bandello F: Repeated intravitreal dexamethasone implant (Ozurdex ) for retinal vein occlusion. Ophthalmologica 2013; 229: 21-25.
10. Parodi MB, Iacono P, De Benedetto U, Cascavilla M, Bandello F: Rebound effect after intravitreal dexamethasone implant for the treatment of macular edema secondary to central retinal vein occlusion. J Ocul Pharmacol Ther 2012; 28: 566-568.
11. Parodi MB, Iacono P, Cascavilla M, Zucchiatti I, Bandello F: Compassionate use of dexamethasone implant for the treatment of macular edema secondary to central retinal vein occlusion in a clinical setting. Acta Ophthalmol 2012; 90: 322-323.
12. Rishi P, Rishi E, Kuniyal L, Mathur G: Shortterm results of intravitreal dexamethasone implant (OZURDEX ) in treatment of recalcitrant diabetic macular edema: a case series. Oman J Ophthalmol 2012; 5: 79-82.
13. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D: Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011; 52: 80-86.
14. Kiss CG, Barisani-Asenbauer T, Simader C, Maca S, Schmidt-Erfurth U: Central visual field impairment during and following cystoid macular oedema. Br J Ophthalmol 2008; 92: 84-88.
15. Senturk F, Ozdemir H, Karacorlu M, Karacorlu SA, Uysal O: Microperimetric changes after intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion. Retina 2010; 30: 1254-1261.
16. Rohrschneider K, Bueltmann S, Springer C: Use of fundus perimetry (microperimetry) to quantify macular sensitivity. Prog Retinal Eye Res 2008; 27: 536-548.
17. Spaide RF, Koizumi H, Pozzoni MC: Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 2008; 146: 496-500.
18. Mathew R, Pearce E, Muniraju R, Abdel-Hay A, Sivaprasad S: Monthly OCT monitoring of Ozurdex for macular oedema related to retinal vascular diseases: re-treatment strategy (OCTOME Report 1). Eye (Lond) 2014; 28: 318-326.
19. Joshi L, Yaganti S, Gemenetzi M, Lightman S, Lindfield D, Liolios V, Menezo V, Shao E, Taylor SR: Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol 2013; 97: 1040-1044.
20. Parravano M, Oddone F, Boccassini B, Giorno P, Chiaravalloti A, Tedeschi M, Scarinci F, Varano M: Exploring the morphological and functional retinal changes after dexamethasone intravitreal implant (Ozurdex ) in macular edema due to retinal vein occlusion. Ophthalmic Res 2014; 51: 153-160.